Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 13/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23950303 | 0.89 | ATR (0.42) | ATRSYKACVR1AURKAMTOR | |
| SCHEMBL23925568 | 0.88 | ATR (0.41) | ATRSYKJAK2JAK3ACVR1 | |
| SCHEMBL23950297 | 0.88 | ATR (0.44) | ATRSYKACVR1PIM1 | |
| SCHEMBL23950770 | 0.88 | ATR (0.44) | ATRSYKACVR1AURKAPIM1 | |
| SCHEMBL23950299 | 0.87 | PSD (0.37) | ATRMTOR | |
| SCHEMBL23950547 | 0.83 | SYK (0.43) | ATRSYKJAK2JAK3ACVR1 | |
| SCHEMBL23951142 | 0.82 | SYK (0.47) | ATRSYKACVR1AURKAPIM1 | |
| SCHEMBL23390209 | 0.76 | ATR (0.53) | ATRPIM1 | |
| SCHEMBL23390211 | 0.76 | ATR (0.53) | ATRPIM1 | |
| SCHEMBL23390306 | 0.75 | CYP2A6 (0.39) | PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115443276-B | Pyridopyrimidinone derivatives and their use as arene receptor modulators | 东亚ST株式会社 | 2025-04-18 | — | — | CN | claimed |
| CN-115443276-B | Pyridopyrimidinone derivatives and their use as arene receptor modulators | 东亚ST株式会社 | 2025-04-18 | — | — | CN | disclosed |
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-11 | — | — | US | disclosed |
| CN-115443276-A | Pyridopyrimidinone derivatives and their use as modulators of aromatic hydrocarbon receptors | 东亚ST株式会社 | 2022-12-06 | — | — | CN | disclosed |
| WO-2021210970-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | AHR, ARNT, AIPL1 | ATR 1410/4885SYK 2716/4885JAK2 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.